Healx Funding, Investors & Competitors

Healx has raised $115M across 4 funding rounds, most recently a $47M Series C in August 2024.

See full Healx profile

Last Healx funding round

$47M

Series C · Aug 2024

Cumulative funding Healx raised

$115M

across 4 funding rounds

Key investors in Healx

  • Jonathan Milner
  • Balderton Capital
  • Amadeus Capital Partners
  • Global Brain Corporation
  • Atomico
  • b2venture
  • Trend Investment Group
  • Intel Capital

Healx Overview

About Healx

Healx is a Cambridge, UK-based biotechnology company employing generative AI to accelerate drug discovery for rare diseases. The platform analyzes biomedical data to repurpose approved drugs and nominate novel candidates, targeting over 100 genetic disorders through its HealNet knowledge graph. Founded in 2017, Healx has raised significant venture funding and collaborates with pharmaceutical firms like Takeda on neuroscience pipelines, shortening development timelines from years to months.


Founded

2014

HQ

United KingdomCambridge

Website

healx.ai

Status

Privately held

Customer focus

B2B

Revenue model

Services, Subscription

Healx Funding History

Healx has raised a total of $115M across 4 funding rounds.

Healx's first fundraising round was a $2M seed round in October 2016. The most recent completed round was a $47M Series C in August 2024.

Healx funding rounds

Healx funding rounds
DateStageInvestorsRaisedDeal Summary
Aug 2024Series CAtomico (lead); R42 Group (lead); Global Brain Corporation; Jonathan Milner; Balderton Capital; b2venture; Propel(X); O2h Ventures; VU Venture Partners; Ayana capital$47MHealx is an AI-enabled, clinical-stage biotech company specializing in rare disease drug discovery, founded by David Brown (co-inventor of Viagra) and Tim Guilliams. The company uses its proprietary Healnet platform, powered by generative AI, to identify therapeutic opportunities across rare oncology, renal, and neurodevelopmental disorders. In August 2024, Healx announced a $47 million Series C round co-led by R42 Group and Atomico, with participation from Ayana Capital, Balderton, Btov, Global Brain, Jonathan Milner, O2h, and VU Venture Partners. The funding was used to advance its lead program HLX-1502 through Phase 2 clinical trials for neurofibromatosis Type 1 (NF1), with FDA clearance received to initiate these trials in the U.S. later that year. Prior to this round, Healx had raised approximately $68 million, including a $56 million Series B in 2019, bringing total funding to over $110 million. As a clinical-stage biotech company with no marketed products, Healx does not publicly disclose revenue or EBITDA metrics. CEO Tim Guilliams indicated the company expected clinical results in the first half of 2026, with potential regulatory registration to follow depending on trial outcomes and FDA interactions.
Oct 2019Series BAtomico (lead); Global Brain Corporation; Trend Investment Group; Jonathan Milner; Balderton Capital; b2venture; Amadeus Capital Partners; Intel Capital$56MHealx is a Cambridge, UK-based AI-powered biotech company that develops treatments for rare diseases using proprietary artificial intelligence software to analyze biomedical data and accelerate drug discovery. The platform aims to advance treatments to clinical trials faster and more cost-effectively than traditional methods, targeting around 7,000 rare diseases affecting 400 million patients worldwide in a market estimated at $220 billion. In October 2019, Healx raised $56 million in a Series B round led by Atomico, with participation from Intel Capital, Global Brain, btov Partners (b2venture), and existing investors including Balderton Capital, Amadeus Capital Partners, and angel investor Jonathan Milner. This followed a $10 million Series A the previous year. The Series B funds were allocated to launch the global Rare Treatment Accelerator programme, partnering with patient groups to develop treatments like those for fragile X syndrome, the leading genetic cause of autism, and to expand into Europe while building a therapeutic pipeline. CEO Tim Guilliams noted the unexpected timing due to Atomico's approach, aligning on rapid scaling. Atomico principal Irina Haivas highlighted Healx's strong tech and drug expertise as key to addressing unmet needs in rare disease drug discovery, aiming to reach clinic in 24 months versus the decade-long industry norm. Healx continued raising capital post-2019, including a $47 million (£37 million) Series C in August 2024 co-led by R42 Group and Atomico to advance pipeline assets like HLX-1502 into Phase 2 trials for neurofibromatosis type 1, with partnerships like the Children’s Tumor Foundation providing milestone payments.
Jul 2018Series ABalderton Capital (lead); Trend Investment Group; Jonathan Milner; Ruttenberg Gordon Investments; Amadeus Capital Partners$10MHealx is a Cambridge, UK-based AI-powered company that uses its HealNet platform to discover and develop treatments for rare diseases, affecting 350 million people worldwide where 95% lack approved treatments. The platform integrates scientific literature, clinical trial results, and proprietary data into a biomedical knowledge graph to predict therapeutic relationships, accelerating discovery from years to months. On July 26, 2018, Healx raised a $10 million Series A funding round led by Balderton Capital, with participation from existing investors Amadeus Capital Partners and Jonathan Milner. The investors also included Ruttenberg Gordon Investments and Trend Investment Group as per query details. The funds supported expanding the multidisciplinary team of software engineers, data scientists, pharmacologists, and drug development experts, and advancing AI and machine learning technologies. Founded by Tim Guilliams of Cambridge Rare Diseases Network and David Brown, co-inventor of Viagra and former Roche drug discovery head, Healx focuses on repurposing existing drugs for niche rare disease populations in collaboration with patient groups. This approach addresses the inefficiencies of traditional drug discovery, which is slow, high-failure, and uneconomic for rare diseases. The 2018 Series A preceded a $56 million Series B in October 2019 led by Atomico, with participation from Balderton, Amadeus, Jonathan Milner, Intel Capital, Global Brain, and btov Partners, used to build a clinical-stage pipeline including fragile X syndrome treatments and launch the Rare Treatment Accelerator.
Oct 2016SeedAmadeus Capital Partners (lead); Jonathan Milner (lead); Cambridge Angels group; Campden Hill Capital$2M-

Who has invested in Healx?

16 investors have backed Healx across its funding rounds, including Jonathan Milner, Balderton Capital, Amadeus Capital Partners, Global Brain Corporation, Atomico and b2venture.

Lead investors include Atomico, R42 Group, Balderton Capital, Amadeus Capital Partners and Jonathan Milner.


Healx Investors

Investors in Healx by funding rounds participated
InvestorHQRoundsRoleFirst check
Jonathan MilnerUnited StatesUnited States4LeadOct 2016
Balderton CapitalUnited KingdomLondon3LeadJul 2018
Amadeus Capital PartnersUnited KingdomCambridge3LeadOct 2016
Global Brain CorporationJapanTokyo2ParticipantOct 2019
Trend Investment GroupChinaShanghai2ParticipantJul 2018
b2ventureGermanyBerlin2ParticipantOct 2019
AtomicoUnited KingdomLondon2LeadOct 2019
Propel(X)United StatesSan Francisco, CA1ParticipantAug 2024
O2h VenturesUnited KingdomCambridge1ParticipantAug 2024
VU Venture PartnersUnited StatesSan Francisco, CA1ParticipantAug 2024
Ruttenberg Gordon InvestmentsUnited StatesNew York City, NY1ParticipantJul 2018
R42 GroupUnited StatesSan Francisco, CA1LeadAug 2024
Cambridge Angels groupUnited KingdomLondon1ParticipantOct 2016

This data is available for Pro users. Sign up to see all 16 Healx investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Healx Competitors

Healx competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.

Public and private companies comparable to Healx
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AstromechUnited StatesUnited StatesPrivate--$3.8B-
Chai DiscoveryUnited StatesSan Francisco, CAPrivate$48M-$3.8B-
AnthropicUnited StatesSan Francisco, CAPrivate$47B-$965B20.5x
OpenAIUnited StatesSan Francisco, CAPrivate$25B-$852B34.1x
SAPGermanyGermanyPublicly listed$42B$13B$248B5.4x
SnowflakeUnited StatesUnited StatesPublicly listed$4.7B($1.3B)$119B21.0x

Healx Public Comps

Healx is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x

This data is available for Pro users. Sign up to see all Healx competitors and their valuation data.

Start Free Trial

Common questions about Healx

When was Healx founded?Healx was founded in 2014.
Where is Healx headquartered?Healx is headquartered in Cambridge, United Kingdom.
Is Healx publicly listed?No, Healx is a private, VC-backed company.
How much funding has Healx raised?Healx has raised $115M across 4 funding rounds.
What was Healx's last funding round?Healx's last funding round was a $47M Series C in August 2024, led by Atomico and R42 Group.
Who are Healx's investors?Healx's investors include Jonathan Milner, Balderton Capital, Amadeus Capital Partners, Global Brain Corporation, Trend Investment Group, b2venture, Atomico, Propel(X), O2h Ventures, VU Venture Partners and 6 others.
Which companies are comparable to Healx?Companies comparable to Healx include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake.

See companies similar to Healx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial